mTOR is an evolutionarily conserved kinase that plays a critical role in sensing and responding to environmental determinants. Recent studies have shown that fine-tuning of the activity of mTOR complexes contributes to organogenesis and tumorigenesis. Although rapamycin, an allosteric mTOR inhibitor, is an effective immunosuppressant, the precise roles of mTOR complexes in early T-cell development remain unclear. Here we show that mTORC1 plays a critical role in the development of both early T-cell progenitors and leukemia. Deletion of Raptor, an essential component of mTORC1, produced defects in the earliest development of T-cell progenitors in vivo and in vitro. Deficiency of Raptor resulted in cell cycle abnormalities in early T-cell progenitors that were associated with instability of the Cyclin D2/D3-CDK6 complexes; deficiency of Rictor, an mTORC2 component, did not have the same effect, indicating that mTORC1 and -2 control T-cell development in different ways. In a model of myeloproliferative neoplasm and T-cell acute lymphoblastic leukemia (T-ALL) evoked by Kras activation, Raptor deficiency dramatically inhibited the cell cycle in oncogenic Kras-expressing T-cell progenitors, but not myeloid progenitors, and specifically prevented the development of T-ALL. Although rapamycin treatment significantly prolonged the survival of recipient mice bearing T-ALL cells, rapamycin-insensitive leukemia cells continued to propagate in vivo. In contrast, Raptor deficiency in the T-ALL model resulted in cell cycle arrest and efficient eradication of leukemia. Thus, understanding the cell-contextdependent role of mTORC1 illustrates the potential importance of mTOR signals as therapeutic targets. m TOR is a serine/threonine kinase that has a central role in the regulation of cell growth and cell metabolism and forms two functionally different complexes, named mTORC1 and mTORC2 (1) . The Raptor subunit is specific to the mTORC1 complex, and Rictor is specific to mTORC2. One of the major upstream signal transduction pathways of mTORC1 is the phosphatidylinositol-3 kinase (PI3K)-AKT pathway. AKT activates mTORC1 via PRAS40 and the tuberous sclerosis 1/2 (TSC1/2)-Rheb pathway. The TSC1/2 complex is an established mTORC1 suppressor, and its protein destabilization via extracellular-signalregulated kinase (ERK) activates mTORC1 (2) . Because the GTPbound form of Ras interacts with and activates PI3K and ERK, Ras is also an activator of mTORC1 (3) .
Abnormalities of mTOR signals are frequently detected in patients with one of several types of leukemia (4, 5) . In particular, alterations in PTEN, PI3K, or AKT frequently occur in patients with T-cell acute lymphoblastic leukemia (T-ALL) (6) . In a mouse model, deletion of Pten during hematopoiesis demonstrated that Pten is critical for suppressing the development of leukemia (7) (8) (9) . Furthermore, studies using Raptor-or Rictordeficient mice revealed that activation of mTORC1 or -2 is required for the leukemogenesis evoked by Pten loss (10, 11) . However, the involvement of mTORC1 in leukemogenesis associated with other oncogenic signals, such as Ras, is not well understood. More importantly, it has remained unclear whether mTORC1 inactivation would eradicate T-ALL.
Rapamycin is a potent immunosuppressant that induces severe thymic atrophy in rodents. However, a study of conditional deletion of Rheb, which encodes an mTORC1 activator, or of mTOR with a Cd4-Cre transgene showed that mTORC1 inactivation does not result in apparent thymic phenotypes under steady-state conditions (12) , leading to the possibility that rapamycin may affect T-cell development in an mTORC1-independent manner. In addition, it has been reported that 4E-BP1 is a rapamycininsensitive mTORC1 substrate, suggesting that rapamycin treatment does not necessarily represent mTORC1 inactivation (13) .
Significance mTOR, a kinase that senses and responds to nutrients, plays critical roles in organogenesis and tumorigenesis. Although mTOR inhibitors have been developed as immunosuppressants and anticancer drugs, it has remained controversial whether such medications contribute to cancer eradication. In addition, mTOR inhibition by chemical inhibitors is complicated because it may not produce predictable inhibition of the mTOR complexes mTORC1 and mTORC2. By using a genetic approach, our study clearly demonstrates that mTORC1, but not mTORC2, is essential for cell cycling of early T-cell progenitors. More importantly, we reveal that loss of mTORC1 efficiently eradicates T-cell acute lymphoblastic leukemia cells, but not myeloid leukemia. Thus, understanding the cell-context-dependent role of mTOR illustrates the potential importance of mTOR signals as therapeutic targets.
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Thus, the precise roles of mTOR complexes in T-cell development remain unclear.
In this study, we focused on the role of mTOR in T-cell development. Our data clearly show that mTORC1, but not mTORC2, is essential for cell cycling of the earliest T-cell progenitors, but not myeloid progenitors. In addition, we found that mTORC1 inactivation effectively prevented the induction of T-ALL, but not myeloproliferative neoplasm (MPN), induced by oncogenic Kras, indicating that mTORC1 is specifically essential for T-cell development and leukemogenesis. Importantly, we revealed that inactivation of mTORC1 by Raptor deficiency efficiently eradicates Notch-driven T-ALL in vivo. Thus, dissection of mTOR signals in vivo should suggest therapeutic approaches that will successfully eradicate many types of cancer.
Results
Raptor Deficiency Impairs Development of Early T-Cell Progenitors in Vivo. To understand the physiological role of mTORC1 in T-cell development, we evaluated the effects of mTORC1 inhibition by rapamycin treatment or the genetic deletion of the Raptor gene. As previously reported (14) , rapamycin treatment resulted in apparent atrophy of the thymus in wild-type mice and hypophosphorylation of S6, a representative mTORC1 downstream target, in thymocytes ( Fig. 1A and Fig. S1 A-G). Higher doses of rapamycin did not show a significant change of effects on thymic atrophy and the proportion of thymocytes (Fig. S1 A-F) . We analyzed thymuses from tamoxifen (TAM)-induced Raptor-deficient mice (Raptor fl/fl ;Rosa26-CreER T2 ), in which Raptor is efficiently deleted in all tissues, including hematopoietic cells, by 2 wk after TAM treatment. We found that, similar to rapamycin treatment, Raptor deficiency resulted in thymic atrophy (Fig. 1A and Fig.  S1H ). Flow cytometric analysis revealed that Raptor deficiency dramatically inhibited the development of CD4/CD8 doublepositive (DP) cells (Fig. 1B) . Although the degree of T-cell development in Raptor-deficient mice varied highly among individuals (Fig. 1B) , three of nine mice showed a particularly severe reduction of DP cells (Fig. 1B) . Rapamycin treatment produced similar defects, but to a lesser extent (Fig. 1B and Fig. S1 C and F) . Next, to examine the effects of T-cell-specific Raptor deficiency, we evaluated thymic phenotypes in mice lacking Raptor in T cells (Raptor fl/fl ;Lck-Cre, Fig. S2A ). However, we unexpectedly did not find any significant reduction of thymocytes (Fig. S2B) or apparent blockage of cell differentiation in thymocytes (Fig. S2C) (Fig. S2D ), indicating that Cre recombinase was not fully expressed or activated at stages DN3 in our experimental condition. Furthermore, we found that Raptor protein was not reduced even in the RFP-positive (Cre-expressing) DN3 (Fig. S2E) , presumably due to the long half-life of the Raptor protein. Accordingly, the phosphorylation level of 4E-BP1 was also comparable to that of the control (Fig. S2F ) in DN3 cells. In contrast, CD4/CD8 DP cells showed clear induction of RFP expression (Fig. S2D) , reduced Raptor protein (Fig. 2E) , and reduced phosphorylation of 4E-BP1 (Fig. S2F ), indicating that Raptor is dispensable for T-cell development at the DP stage.
Next, we focused on phenotypes in thymic DN cells of Raptor fl/fl ; Rosa26-CreER T2 mice. We found that S6 exhibited relatively high levels of phosphorylation in early T-cell progenitors, including DN1 and DN2 (CD44
, suggesting that activation of mTORC1 may be crucial for the development of early T-cell progenitors (Fig. 1C) . Rapamycin remarkably increased the proportion of DN3 cells and decreased the proportion of DP cells ( Fig. 1 B and D and Fig. S1 C, D, and F), indicating that rapamycin mainly blocked differentiation from DN3 to DP in vivo. Raptor deficiency resulted in an increased proportion of DN1, whereas the proportions of DN2 and DN3 were reduced (Fig. 1D) . We confirmed that the Raptor gene was completely deleted in DN3 cells from thymus ( Fig. S2G ), even in cases that showed milder phenotypes. Although the absolute number of Raptor-deficient DN1 in thymus varied among samples, there was no significant difference compared with control ( Fig. S2 H and I) . In contrast, the absolute number of DN2 and DN3 was dramatically reduced in Raptor-deficient mice ( Fig. S2 J and K). These data suggest that development of early T-cell progenitors, particularly at DN2, may be impaired by Raptor deficiency in vivo. failure of DN2 and DN3 cells to develop, indicating that mTORC1 inactivation results in failure of development from DN1 to DN2. To confirm that inactivation of mTOR kinase itself would produce the same defective phenotypes, we generated mTOR fl/fl ; Rosa26-CreER T2 mice (Fig. S4 A-D) and evaluated the effect of mTOR deficiency on T-cell development. As expected, mTOR deficiency also suppressed the proliferation and development of T cells in vitro (Fig. S3 B and C) , as we had observed in Raptordeficient cells. Furthermore, to investigate the role of mTORC2 on T-cell development in this experimental condition, we generated Rictor fl/fl ;Rosa26-CreER T2 mice. Rictor-deficient cells showed comparable proliferative capacity to the control (Fig. S3 D and E) after 11 d in culture, and differentiation of stages DN2 and DN3 was normal. After culture for a longer period (16 d) , Rictor deficiency eventually resulted in a reduction of the total cell number, and DP cells failed to develop (Fig. 1 G and H) , indicating that mTORC2 plays a critical role in the development of DP cells. These results clearly demonstrate that mTORC1 and mTORC2 control T-cell development in a different manner and that mTORC1 plays a critical role in the earliest development of T-cell progenitors. Progenitors. To investigate how mTORC1 controls development of the early T-cell progenitors, we evaluated the expression profiles of selected genes in T-cell development. Several genes that were up-regulated or down-regulated during T-cell development were regulated in the same manner in Raptor-deficient thymocytes (Fig. S5 A-G) , suggesting that Raptor deficiency does not directly affect the differentiation program. Consistent with these data, DN cells from Raptor-deficient mice showed T-cell receptor β (TCRβ) gene rearrangement (Fig. S5H) . Next, we examined the cell cycle status of Raptor-deficient T-cell progenitors by using K i -67 and Hoechst33342 staining. Raptor-deficient DN1 cells showed a dramatic decrease of the S/G2/M phases and an increase of the G0/G1 phases ( Fig. 2A) , indicating that Raptor deficiency caused a defect in the G1/S transition in early T-cell progenitors in thymus. Rapamycin also inhibited the cell cycle of DN1, but to a lesser extent than Raptor deficiency. Although Raptor deficiency significantly increased the number of 7AAD + dead cells, no remarkable increase of apoptotic cells (7AAD -AnnexinV + ) was seen (Fig. 2B) . Consistent with this result, amounts of survival-related (Bcl-xL and Bcl-2) and apoptosis-related (cleaved PARP and cleaved Caspase-9) proteins were not affected by Raptor deficiency in Tcell progenitors (Fig. S6A ). These data suggest that mTORC1 inactivation may primarily cause a failure of the cell cycle, resulting in cell death. Thus, mTORC1 activation is essential for T-cell development in thymus, presumably because it supports proliferation of the earliest T-cell progenitors.
Cyclin D2/D3-CDK6 Protein Complex Is Stabilized by mTORC1 Activity.
To find mTORC1 targets responsible for phenotypes of Raptordeficient early T-cell progenitors, particularly in DN1, we performed Western blotting. We found that Raptor deficiency induced a band-shift of p70S6K and 4E-BP1 proteins in all hematopoietic subpopulations, including DN1 cells (Fig. 2C) , and confirmed that phosphorylation of 4E-BP1 was reduced (Fig. S6A) , indicating that mTORC1 was completely inactivated. The Cyclin D3-CDK6 complex has an indispensable role in the cell cycle of normal T-cell progenitors and T-ALL cells (17, 18) . Because we observed the apparent cell cycle arrest only in T-cell progenitors, we evaluated the protein expression of Cyclin D1, D2, and D3 and CDK6 in several subpopulations of Raptor-deficient hematopoietic cells (Fig. 2C) . Cyclin D2 and D3 expression was dramatically reduced in Raptor-deficient cells in differentiated hematopoietic subpopulations. Consistent with a previous report that CDK6 expression is regulated by the Notch-AKT pathway (17), we found that the CDK6 protein level was increased in DN3 cells in association with the up-regulation of Notch target genes (Tcf7, Il2ra, Fig. S5 D and E) . Although Raptor deficiency did not abrogate the up-regulation of CDK6 expression in DN3, the protein level of CDK6 in the Raptor-deficient T-cell progenitors appeared to be lower than in the control (Fig. 2C) . In contrast, CDK6 expression was increased in Raptor-deficient myeloidlineage cells. Raptor deficiency also strongly reduced the protein level of Cyclin D3 in the in vitro culture system (Fig. 2D) . Although the CDK6 protein level varied among samples, it was decreased to a lesser extent than Cyclin D3 (Fig. 2D) . The mRNA transcriptional levels of Cyclin D3 and CDK6 were not affected by Raptor deficiency in DN3 cells (Fig. 2E) . Protein levels of Cyclin D3 and CDK6 were not affected by Rictor deficiency (Fig. 2F) . These data suggest that mTORC1 activity may control the Cyclin D2/D3-CDK6 complex via posttranscriptional mechanisms. Because the amount of Cyclin D3 protein is regulated by ubiquitinmediated proteolysis via PI3K activity (19), we next examined the roles of mTORC1 in proteolysis-mediated regulation of Cyclin D2/D3 in T cells. When we treated T cells with a proteasome inhibitor, MG-132, in vitro, the reduction of Cyclin D2/D3 and CDK6 by mTORC1 inactivation was reversed in both DN1 cells and DN3 cells (Fig. 2G and Fig. S6B ). These data suggest that mTORC1 controls the cell cycle of early T-cell progenitors, including DN1 and DN3, by stabilizing the Cyclin D2/D3-CDK6 complex. , and Raptor Δ/Δ Kras G12D cells ( Fig. 3 A and B) . The proportion of Raptor Δ/Δ tester cells, compared with competitor cells, was dramatically reduced in thymus 3 wk after TAM administration, whereas it was decreased only slightly in BM. Raptor deficiency dramatically inhibited the proliferative effects of Kras G12D on the cell competition in thymus. mTORC1-independent phosphorylation of S6 was observed in Mac-1 + myeloid cells (Fig. 3C) . In contrast, both S6 and 4E-BP1 were hypophosphorylated in Raptor-deficient T cells, indicating that the phosphorylation was completely controlled by mTORC1 in T cells (Fig. 3C) . Raptor deficiency inhibited the cell cycle in oncogenic Kras-expressing T-cell progenitor cells, but not in Mac-1 + myeloid cells (Fig. 3D) . When we analyzed the Raptor Δ/Δ Kras G12D mice at 2 wk post-TAM, we found that the combination of Raptor deficiency and Kras activation resulted in an increase of the number of monocytes and granulocyte-macrophage progenitors (GMPs) (Fig. S7 A-E) . This finding was in contrast to the severe thymic atrophy that we observed in these mice (Fig. S2 H-K) , highlighting the interesting difference in the roles of Raptor between myeloid and lymphoid cells. Consistent with the hypophosphorylation of 4E-BP1, rates of new protein synthesis were significantly reduced in cycling Raptor-deficient progenitors (Fig. S7F) . These data indicate that the impact of mTORC1 deficiency on cell cycle status varies substantially depending on the cell context and that Raptor is critical for the development and proliferation of T cells, even when the T cells are oncogenically activated.
Inactivation of mTORC1 Prevents Oncogenic Kras-Induced T-ALL
To evaluate the effect of mTORC1 inactivation on the leukemogenesis induced by oncogenic Kras, we performed a long-term observation of hematopoiesis in mice bearing mutant cells. Mice bearing control or Raptor Δ/Δ cells survived to the end of the experiment (Fig. 3E) . Most of the mice with Kras G12D cells died by 83 d after TAM treatment (Fig. 3E) , with an associated overt increase of white blood cells (WBC) (Fig. 3F) . The increase of WBCs was due to the propagation of CD4 +
CD8
+ cells in some cases, indicating that the mice had developed T-ALL (Fig. 3G) . In contrast, mice with Raptor Δ/Δ Kras G12D cells died by 131 d after TAM treatment (Fig. 3E) ; three of seven Raptor Δ/Δ Kras G12D mice showed an elevated WBC count by 16 wk post-TAM (Fig. 3F) (Fig. 3G) . All Raptor Δ/Δ Kras G12D mice with elevated WBC counts showed an increase of the Mac-1
+

Gr-1
-myeloid-lineage cell population in PB (Fig. 3G and Fig. S7G ), suggesting that the cause of death of these mice may have been MPN. Thus, inhibition of mTORC1 dramatically suppressed T-ALL development in response to oncogenic Kras expression.
mTORC1 Inactivation Efficiently Eradicates Notch-Driven T-ALL. To investigate the effects of mTORC1 inhibition on the proliferation of T-ALL in vivo, we transplanted cells from thymuses of recipient mice that showed obvious signs of T-ALL development into new recipients (Fig. S8 A-C) . Although the survival of recipient mice bearing Kras-evoked T-ALL cells was significantly prolonged by rapamycin treatment (Fig. 4A and Fig. S8D ), T-ALL cells continued to propagate in BM and spleen of rapamycintreated mice (Fig. S8E) , and the mice eventually died, indicating that rapamycin-insensitive T-ALL can survive and proliferate in vivo. Hence, we investigated the impact of complete mTORC1 inactivation on eradication of T-ALL cells in vivo. To do so, we generated a T-ALL model in which an active Notch1 (NICD) gene, along with GFP as a marker, is retrovirally introduced into BM cells from Raptor fl/fl ;Rosa26-CreER T2 mice (Fig. S9A ). These BM cells are then transplanted into lethally irradiated mice. We also evaluated the effect on the behavior of T-ALL of hyperactivation of mTORC1 by deletion of Tsc1, which is a negative regulator of mTORC1. Tsc1 deficiency significantly shortened the survival of T-ALL mice, whereas Raptor deficiency completely suppressed death in the T-ALL mice (Fig. 4B) . As expected, Tsc1 deficiency enhanced propagation of GFP + T-ALL cells in the PB (Fig. 4C) . In contrast, Raptor deficiency dramatically decreased propagation of T-ALL cells in the PB (Fig. 4C) . Furthermore, we found that, unlike rapamycin treatment, Raptor deficiency efficiently eradicated T-ALL in BM and spleen (Fig. 4D) . The cell cycle was apparently inhibited in Raptor-deficient T-ALL cells (Fig. 4E) . The expression of Cyclin D2 and D3, but not CDK6, was strongly suppressed in Raptor-deficient T-ALL cells (Fig. 4F and Fig. S9B ). The expression levels of apoptosis-related molecules were not remarkably affected by Raptor deficiency in T-ALL cells (Fig. S9B ). These data suggest that mTORC1 strictly controls Cyclin D2 and D3 protein levels in all types of cells, whereas CDK6 protein may be controlled by mTORC1 in a cell-contextdependent manner. In control T-ALL mice, leukemia cells disseminated and proliferated in several nonhematopoietic organs, including liver and lung, but we did not find any dissemination of Raptor-deficient leukemia cells (Fig. 4G and Fig. S9C ). In contrast, Tsc1 deficiency exacerbated the dissemination and proliferation of T-ALL cells in nonhematopoietic organs (Fig. 4G and Fig. S9C ). Furthermore, we investigated whether Raptor deficiency can deplete leukemia cells in a more aggressive T-ALL model. It was recently reported that oncogenic mutations of NRAS and KRAS cause early T-cell precursor ALL, an aggressive subtype of T-ALL (24) . Because we observed that T-ALL cells driven by oncogenic Kras and associated with Notch1 mutations were rapamycin-insensitive ( Fig. 4A and Fig. S8E ), we combined Notch-driven T-ALL with Kras activation and evaluated the effect of Raptor deficiency in this model. We found that the addition of oncogenic Kras expression accelerated onset of Notch1-driven T-ALL. However, Raptor deficiency dramatically suppressed the propagation of leukemia cells even in this aggressive T-ALL model (Fig. S9D ). These data demonstrate that complete mTORC1 inactivation, but not rapamycin treatment, is highly effective for the eradication of T-ALL cells in vivo.
Discussion
Essential Role of mTORC1 in Early T-Cell Progenitor Development.
Although rapamycin is a well-known allosteric inhibitor of mTORC1 and acts as an immunosuppressant, it has remained unclear how rapamycin affects T-cell development. Several studies showed that rapamycin blocks IL-2-dependent T-cell proliferation (25, 26) . Because DN2 cells, but not DN1 cells, express an IL-2 receptor (IL-2Rα; CD25), mTORC1 was suggested to be activated at DN2. However, in this study, we found that both DN1 and DN2 showed increases in S6 phosphorylation and that mTORC1 deficiency by Raptor deletion caused a dramatic abnormality of cell cycling of DN1 cells, leading to developmental failure of DN2 and DN3. In contrast, although rapamycin induced remarkable thymic atrophy, similar to Raptor deficiency, it blocked differentiation from DN3 to DP, but not the DN1-DN2 transition; its effect on T-cell development thus appears to be different from the effect of loss of mTORC1 activation. Prolonged treatment with rapamycin inhibits not only mTORC1, but also mTORC2 in some cell lines (27) . In our experiment, although Rictor deficiency did not disrupt the development of early T-cell progenitors, DP cells failed to develop, indicating that mTORC2 is essential for T-cell development at later stages than mTORC1. Because we did not detect any reduction of 4E-BP1 phosphorylation in Rictor-deficient cells in our experimental setting, the defective phenotype of T-cell development caused by Rictor deficiency is independent of mTORC1. These data clearly demonstrate that mTORC1 and mTORC2 have distinct roles in T-cell development and suggest that the effects of rapamycin on T-cell development may be due to partial inhibition of mTORC1 activity, inhibition of mTORC2, or their combination.
Although a slight reduction of Mcl-1 protein was observed in normal T-cell progenitors and T-ALL cells after the Raptor deletion ( Fig. S6A and Fig. S9B ), we did not detect any sign of apoptosis ( Fig. 2B; Fig. S6A; Fig. S9B ). Mcl-1 is reported to be a potent downstream effector of mTORC1 signaling (28) , but reduction of only this molecule may be insufficient to induce apoptosis in Raptor-deficient T-cell progenitors and T-ALL cells. One of the main reasons for the defective propagation of early T-cell progenitors with mTORC1 deficiency was the inhibition of the G1/S transition in DN1 cells. Evaluation of the expression of cell cycle regulators showed that Cyclin D2/D3-CDK6 protein levels were consistently reduced by Raptor deficiency in DN cells. Cyclin D3 is an essential D-type cyclin for normal expansion of T-cell progenitors (18) . Cyclin D2 and D3 have nonredundant roles in T-cell development (29) . Cyclin D3 deficiency is sufficient to reduce susceptibility to T-cell malignancies. Interestingly, Cyclin D3 deficiency reduces BM cellularity caused by defective expansion of granulocytes, but not of hematopoietic stem cells and GMPs (30) , just as we observed in Raptor-deficient mice. Although T-ALL cells were efficiently eradicated when mTORC1 was inactivated in vivo, the reduction of CDK6 protein was not observed, suggesting that Cyclin D2 and D3 are major downstream targets of mTORC1. Some previous studies using rapamycin reported that the Cyclin D3 expression level is controlled by mTOR, but there were two possible mechanisms, i.e., translational regulation (31) and posttranslational regulation via the ubiquitin-proteasome pathway (32) . In addition, 4E-BPs reportedly regulate mTORC1-mediated cell proliferation by translational control of Cyclin D3 in mouse embryonic fibroblasts (33) . In our experiment, we found that mTORC1 deficiency, and not mTORC2 deficiency, induces protein degradation of Cyclin D2 and D3 mainly in a proteasome-dependent manner in T cells. These data suggest that Cyclin D2 and D3 are tightly regulated by mTORC1 activity in multiple ways. Deep understanding of the dependency of cell cycle regulation on the mTORC1-Cyclin D2/D3 pathway in different tissues will be important for successful mTORC1-targeted therapy. Efficient Eradication of T-ALL, but Not Acute Myeloid Leukemia, by mTORC1 Inactivation. In contrast to the effective suppression of T-ALL progression by rapamycin, the cytostatic effect of rapamycin was not sufficient for the total eradication of T-ALL cells. The presence of rapamycin-insensitive mTORC1 substrates, like 4E-BP1, may account for this incomplete effect (13) . Alternatively, the cytostatic effect of rapamycin on T-ALL may be mediated by mTORC2 inhibition because it was reported that Rictor deficiency significantly, but not completely, suppresses Notchdriven T-ALL (34), which is similar to the effect of rapamycin observed in our study. Higher doses of rapamycin in vivo may have stronger therapeutic efficacy for T-ALL, but may also have unexpected side effects because prolonged treatment with a higher dose of rapamycin inhibits mTORC2 as well as mTORC1 (12, 27, 35) . Based on our findings, we believe that complete inhibition of mTORC1, but not mTORC2, would contribute to the therapeutic eradication of T-ALL. In our previous study with an acute myeloid leukemia (AML) model, we showed that, although mTORC1 deficiency significantly suppresses leukemia progression by causing apoptosis of differentiated leukemia cells, mTORC1 does not control the cell cycle in undifferentiated AML cells in vivo (36) . Therefore, we believe that a detailed comparative analysis of downstream target molecules between AML and T-ALL would lead to a deeper understanding of the molecular mechanisms by which mTORC1 controls the behavior of leukemia. Although several ATP-competitive mTOR inhibitors appear to have potent anticancer effects, a potential drawback to these agents is their inhibition of multiple targets, which could lead to unwanted side effects or serious damage to normal tissues. Our study revealed that mTORC1-specific inhibition contributes to the eradication of T-ALL cells. The identification of targets downstream of mTORC1 or development of an mTORC1-specific inhibitor would contribute to the development of efficient and specific anticancer therapeutics. 
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